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Abstract   
 
Background: Unplanned pregnancy remains a major problem in the United States, despite the 
widespread usage of contraception. Improper and inconsistent usage of short acting reversible 
contraception contributes to the unplanned pregnancy epidemic. Hormonal and copper 
intrauterine devices are safe and effective alternatives, but usage in the Unites States remains 
low.  
 
Methods:  An extensive search of MEDLINE-Ovid, CINAHL, and Web of Science was 
conducted. Keyword terms included: long-acting reversible contraception, contraception, cost 
effectiveness, and levonorgestrel-releasing intrauterine system. The studies were limited to the 
English language and those done on humans. Only publications from the last fifteen years were 
considered. The articles were further limited to studies done in the United States. References of 
articles were reviewed for further sources.  
 
Results:  A total of 47 articles were reviewed and three met inclusion criteria. The first two 
studies were economic analyses of the use of hormonal IUDs. The third study is a retrospective 
cohort which included an economic analysis. Two of the studies were funded in part by Bayer, a 
drug company that has a vested interest in IUDs being cost-effective. The quality of the data 
remains high.  
 
Conclusion:  The hormonal and copper intrauterine devices are safer, more cost effective 
alternatives to oral contraceptive pills. They require a one-time insertion and last for several 
years. They allow the user privacy and peace of mind, while approaching effectiveness levels of 
sterilization.  
 
Keywords:  long-acting reversible contraception, contraception, cost effectiveness, and 
levonorgestrel-releasing intrauterine system (LNG-IUS).  
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The Intrauterine Device in Women of Childbearing Age Has A 
Greater Long-Term Cost-Benefit than Oral Contraception Pills 
BACKGROUND 
The CDC lists family planning as one of the top ten public health triumphs of the 20th 
century1. Female contraception allows women to control the timing of pregnancy and family 
size, while directly impacting their opportunities in education, workforce participation, and 
income stability. Reversible methods of contraception include hormonal short acting reversible 
contraception (SARC), barrier methods, withdrawal, and long-acting reversible contraception 
(LARC). SARC methods remain the most popular, with 55% of contraceptive users electing for 
oral contraception pills, a patch, a vaginal ring, or injections (Table 1)2. The oral contraceptive 
pill (OCP) is the most widely used method, even though improper or inconsistent use contributes 
to a high rate of failure. The OCP fails less than 1% of the time when used directly as prescribed, 
while typical inconsistent and incorrect usage results in contraceptive failure 9% (Table 2)2. Thus 
despite the wide varieties of contraceptive options on the market, over fifty percent of 
pregnancies in the United States are unplanned. This results in 3.4 million unintended 
pregnancies per year, 60% of which ended in live birth3.  
In contrast, LARC has the same effectiveness with typical and perfect use2. LARC 
methods include the copper intrauterine device (Paragard), hormonal intrauterine devices 
(levonorgestrel-releasing Mirena, Skyla, and Liletta), and hormonal implants (etonogestrel-
releasing Implanon). These safe methods are not user dependent, have similar effectiveness to 
permanent sterilization, and are associated with rapid return to fertility on discontinuation. The 
IUD is the most popular of these options, but only 10% of contraceptive-using American women 
currently opt for an IUD2.  
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This percentage is growing but remains low due to high initial cost, provider and patient 
education, and provider practice patterns. Heavy resistance to intrauterine devices (IUDs) stems 
from public and health care provider fear. The IUD was introduced to the US in the 1960s. By 
the 1970s several different IUDs were on the market, all of them unregulated by the FDA. The 
Dalkon Shield had a design flaw that introduced bacteria into the sterile uterine environment. 
This design flaw caused serious complications including pelvic inflammatory disease, sterility, 
sepsis, and death4. Early studies on IUDs did not differentiate between the Dalkon Shield and 
other IUDs. The Dalkon Shield was voluntarily pulled from the marked and IUD usage in the 
United States plummeted. IUDs remained popular overseas and have proved to be a safe 
contraceptive option for women.4  
The hormonal IUD Mirena was announced to the United States in 2000, nineteen years 
after being introduced and approved for European markets5. Usage remains low but has tripled in 
the US since 20023. As the popularity of Mirena grew, so did the price. Bayer increased the per 
unit price in March 2010 from $470 to $7036. Out of pocket cost for IUD insertion for women 
with health insurance routinely was $800-1200, making it an unaffordable option for the majority 
of women. Reimbursement for providers from health insurance companies remained an issue and 
the price jump made it infeasible to stock in low income clinics. Bayer had discovered in 
addition to preventing pregnancy, the hormonal IUD was found to reduce endometrial and 
cervical cancer, reduce menorrhagia and provide an alternative treatment for hysterectomies.6  
Despite this, misinformation about LARC remained among health care providers. A 2008 
survey of health care providers found 40% did not offer LARC to patients and less than 50% 
believed nulliparous women were appropriate candidates for IUDs, despite literature proving 
otherwise7. The American College of Obstetricians and Gynecologists endorses IUD use in 
9 
 
adolescents regardless of parity8.  In October 2014 the American Academy of Pediatrics 
amended their reports and recommended LARC as the first line contraception option in 
adolescents9. Pediatricians and family practice providers report a lack of training opportunities as 
a barrier in implementing this recommendation7. Adolescents are some of the most at risk 
populations for unintended pregnancies, accounting for over six hundred thousand live births per 
year3. Unintended pregnancy in women is associated with delayed prenatal care, maternal 
depression, low birth weights, poor infant and maternal outcomes, and low rates of 
breastfeeding10. Adolescent women could benefit from a “fit and forget” method of 
contraception is discreet and lasts for years. With the Affordable Care Act executive mandate 
ordering insurance companies to pay for all methods of contraception, interest in IUDs is 
rising11. This suggests cost was a prohibiting factor in women’s decision to use IUDs. Since an 
IUD lasts for 3-10 years depending on the device, the initial acquisition and insertion cost could 
be compared to the cost of unintended pregnancies. The IUD has the potential to be more cost 
effective than OCP.  
METHODS 
An extensive search of MEDLINE-Ovid, CINAHL, and Web of Science was conducted. 
Keyword terms included: long-acting reversible contraception, contraception, cost effectiveness, 
and levonorgestrel-releasing intrauterine system (LNG-IUS). The studies were limited to the 
English language and those done on humans. Only publications from the last fifteen years were 
considered. The articles were further limited to studies done in the United States. References of 
articles were reviewed for further sources. 
RESULTS 
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A total of 47 articles were reviewed and three met inclusion criteria. The first two 
studies12, 13 were economic analyses of the use of hormonal IUDs. The third study14 is a 
retrospective cohort which included an economic analysis. 
Trussell et al (2013) 
 This economic model study12 evaluated the cost of unintended pregnancy (UP) and long 
acting reversible contraception’s potential to reduce health care costs associated with that UP. 
The study estimated the cost of UP that result from imperfect contraceptive use. The 
contraceptive adherence patterns and rates of UP in the United States were pulled from other 
databases.12  
 The potential savings from widespread IUD use cannot be understated. “Total costs to the 
US taxpayers from UP have been estimated to range from $9.6-12.5 billion a year, whilst annual 
direct medical costs have been estimated to be $5 billion. These costs are theoretically 
avoidable.”12 Half of UP in the United States occur in women who report using contraception3, 
and the contraceptive failure occurs from imperfect adherence. IUD does not rely on perfect user 
compliance, as the device lasts for years after the initial insertion. Trussell et al (2013) compared 
the cost of UP due to imperfect adherence and the potential savings from switching to IUDs. The 
authors created an economic model that took into account the annual number of UP and their 
cost, the cost and use of contraception in the US, the number of UP associated with imperfect 
contraceptive use, and the cost-effectiveness of increased usage of IUDs.12 
 The cost of unintended pregnancy was factored in from the Medicare Fee Schedule and 
multiplied by the number of annual UP. Contraceptive cost included the product cost and the 
associated fees with the provider visit. Product costs were obtained from IMS MIDAS, the Medi-
Span Master Drug Database, and consultations fees were taken from Medicare Fee Schedule12. 
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The authors created three scenarios that looked at 10% of women ages 20-29 who were switched 
from OCP to IUDs, 10% of women aged 20-29 using SARC switched to IUDs, and 10% of 
women aged 20-39 switched to SARC or no method to IUDs. The age range of 20-29 was 
chosen because 53% of UPs in the United States are in this age group.12  
 All three groups achieve cost neutrality within two years. The greatest savings occurred 
when women using no method or a SARC switched to an IUD. Limitations include only 
factoring in a first year failure rate for contraceptive methods. The cost of live birth may be 
underestimated as all prenatal costs were omitted.12  
 
Trussell et al (2014) 
 This is a state transition model study13 looking to prove the cost effectiveness of Skyla 
over SARC methods. The LNG-IUS 13.5mg (Skyla) is a levonorgestrel intrauterine device 
approved for three years of use. It is smaller than Mirena, the other levonorgestrel intrauterine 
device on the market and was designed for nulliparous women. Skyla was compared to SARC 
methods in a cohort of women 20-29 years. This age group in the United States currently uses 
OCP more and IUDs less than any other group13.  
 From an insurance company perspective, the LNG-IUS 13.5mg is a more cost effective 
option than OCP, when the costs of unintended pregnancy and cost of OCP is taken into 
account.13 The LNG-IUS 13.5mg is approved for three years of use in nulliparous and parous 
women. The study considered the cost of the drug in question, provider compensation for 
consultation and insertion, and cost of method failure. The costs were pulled from Medi-Span 
Master Drug Database, the wholesale acquisition price, the Healthcare Cost and Utilization 
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Project data, and the 2012 Medicare Reimbursement Fee Schedule13. Method failure was 
measured in live birth, induced abortion, miscarriage, or ectopic pregnancy.  
The effectiveness of each method was measured by the average number of contraceptive 
failures over a three year time period. “Compared to the SARC comparator, LNG-IUS 13.5mg 
was more effective (64 UP vs 276 UP) and less costly ($1,283,479 USD vs. $1,862,633 USD) in 
a starting cohort of 1000 women aged 20 to 29 years in each arm, over the three year time 
horizon.”13 The results were most sensitive to the probability of failure of OCP, the cost of live 
births, and the continuation rate of the IUD. This analysis has limitations as the cost of adverse 
drug reactions or IUD complications were not included in the study. The cost of UP was derived 
from the Medicare billing schedule, which is lower than private insurers. This study probably 
underestimated the total cost of UP. The failure rates with “typical use” were applied to all three 
years in the prospective study and the authors admit failure rates would likely be lower after the 
first year13, as uncompliant users would fail early and be removed from the study.  
Rodgriuez at al 
 This retrospective cohort study14 examined the cost effectiveness of offering postpartum 
IUD insertion to recent US immigrants with Emergency Medicaid insurance. Undocumented and 
legal immigrants who have been in the United States for less than five years are only eligible for 
health insurance with Emergency Medicaid (EM)14. EM does not cover the cost of prenatal care 
or contraception. The “lack of health insurance is associated with multiple obstetrical and 
neonatal outcomes that are detrimental to the health of the woman and child, and expensive for 
the hospital, society, and the state.”14 The authors created two models for their cost benefit 
scenario: hospital provision of IUDs postpartum and state funding of IUDS postpartum. The 
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costs and benefits were measured by comparing the costs of pregnancies averted over the costs 
of IUD purchase and insertion.  
 The cohort was designed by searching the OHSU database for women with EM insurance 
who had delivered babies at OHSU during 2002. The next four years of hospital data on these 
women was included in the cohort, determine by “pregnancy rates, pregnancy outcomes, 
pregnancy costs, and net revenue by procedure type.”14 The authors estimated the number of 
pregnancies averted by factoring the IUD failure rate, continuation, and expulsion. The IUDs 
were placed immediately postpartum, which is a known risk factor for IUD expulsion. This was 
considered when estimating the number of pregnancies averted. The IUD was offered as a 
reversible form of contraception instead of sterilization.  
 Delivery procedure and contraceptive costs were compared. Possible pregnancy 
outcomes included were cesarean delivery, vaginal delivery, vaginal delivery with sterilization, 
ectopic pregnancy, spontaneous abortion, and threatened abortion. The costs were estimated for 
the state by the amount paid to the hospital for each diagnosis, while the cost for the hospital 
included the charges minus the revenue for the state14. IUD costs included the price of the 
device, insertion time, and removal. The outcomes were measured from hospital records. Cost 
savings differed depending on the state or hospital model. The hospital program had a benefit 
ratio of 0.30, losing $0.70 dollars per dollar spent…”program costs for IUS, insertion, and 
removal are estimated for 1000 women at $328,000.”14 Newborn care generates positive revenue 
for the hospital, while providing IUDs loses the hospital money since they are not being 
reimbursed by EM.  In comparison, the state funded program “would save $2.94 in costs for 
repeated obstetrical care for every state dollar spent on an IUD program.”14   Rodriguez et al14 
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projected that state would spend $2.1 million dollars covering the costs of UP in the following 
four years, while the IUD program could cut that number in half. 
 
DISCUSSION 
When taking into account the cost from unintended pregnancy, IUDS are more cost effective 
than OCP. IUDs prevent a higher number of unintended pregnancies and produce net-cost 
savings. This is driven by the significantly lower failure rates of IUDs, which are also not 
dependent on user compliance2. This makes them suitable for women with irregular access to 
healthcare or irregular routines. While IUDS methods are highly effective in preventing 
unintended pregnancies, they do not provide protection against sexually transmitted infections 
(STIs). None of these studies made any inferences or hypothesis as to costs of STI infection with 
increased IUD use. Further studies must be done to see if there is any correlation.  
 Discontinuation is the key determinant to the cost effectiveness of IUDs. Reasons for 
discontinuation include changes in bleeding patterns, headache, acne, weight gain, expulsion, 
and pregnancy intention. Further investigation needs to be made on pain control during IUD 
insertion. IUD insertion is notoriously more difficult on insertion for nulliparous women, and 
could prove an obstacle for widespread IUD use. Existing literature proves that prophylaxis 
ibuprofen, acetaminophen, or misoprostol do not help with IUD insertion pain15. The majority of 
women experience a discomfort similar to menstrual cramps on insertion, but a small subset of 
17% experience significant pain that needs to be subsequently managed15. Studies on the use of 
lidocaine gel and spray are currently conflicting and inconclusive16. Further study is warranted.  
 The hypothetical models of the previously discussed articles are supported by a recent 
ecological study17 in Colorado (CO). In 2009, twenty eight Title X agencies in CO received 
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funding to support the provision of LARC to patients visiting these clinics. These clinics served 
95% of CO’s low income population and were able to provide LARC at no cost or a sliding 
scale. In the next three years, the number of high risk births, abortions, and WIC caseload 
plummeted17.  The expansion of the Affordable Care Act and contraceptive mandate has the 
potential to replicate the success of the Colorado clinics.  
CONCLUSION 
 
The hormonal and copper IUDs are more cost effective than OCPs. The higher initial cost 
acquiring and inserting the devices is offset by several years of preventing pregnancy. The 
method failure rates approach sterilization, while remaining completely reversible2. The far 
reaching implications are staggering. $5 billion dollars is the estimated medical cost of UP in the 
United States every year2. IUDs are the safe and cost effective answer to avoiding unintended 
pregnancies.  
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Table 1: 
 
 
Contraceptive Method Choice 
Most effective method used in the past month by US women, 2012 
 
 
Method 
Pill 
Condom 
IUD 
Withdrawal 
Injectable  
Vaginal Ring 
Implant 
Patch 
 
Percentage of Contraceptive Users 
25.9 
15.3 
10.3 
4.8 
4.5 
2.0 
1.3 
0.6 
www.guttmacher.org 
 
 
Table 2 
Contraceptive Effectiveness 
Percentage of women who become pregnant after one year of use, by method 
 
Method Perfect Use Typical Use 
Pill 0.3 9 
Condom 2 18 
IUD-levonorgestrel 0.2 0.2 
IUD-Copper T 0.8 0.8 
Withdrawal 4 22 
Injectable 0.2 6 
Vaginal Ring 0.3 9 
Implant 0.05 0.05 
Patch 0.3 9 
  www.guttmacher.org 
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